Abronib 100mg Tablets (10s)

Description

Abronib 100 mg contains abrocitinib, an oral selective Janus kinase 1 inhibitor used for moderate-to-severe atopic dermatitis. It is a prescription medicine intended for use under specialist medical supervision.

• Manufacturer Name: Horizon
• Drug Class: Selective Janus kinase 1 (JAK1) inhibitor and immunomodulator
• Dosage Form: Oral Tablet
• Storage: Store at room temperature in a dry place, protected from excessive heat, moisture, and direct light. Keep in the original packaging and out of reach of children.
• Pack Size: Pack of 10 Tablets

Abronib 100mg Tablets (10s) Available Online in Pakistan

Dwatson offers Abronib 100mg Tablets (10s) at Rs. 5800, with fast, discreet delivery across Pakistan.

Ingredients

• Abrocitinib 100 mg

Benefits

• Treatment of moderate-to-severe atopic dermatitis in eligible patients who have an inadequate response to topical therapies or when topical therapies are not appropriate.
• May reduce eczema-related skin inflammation, itching, and disease severity.

Usage & Safety

For Adult

• The usual recommended dose is 100 mg taken orally once daily, as prescribed by a dermatologist or other qualified healthcare professional.
• Some patients may require dose adjustment, including a higher dose, based on clinical response, tolerability, laboratory results, age, kidney function, liver function, and interacting medicines.
• Swallow the tablet whole with water. It may generally be taken with or without food unless the prescriber gives different instructions.
• Do not start, stop, or change the dose without medical advice. Regular monitoring may include blood counts, lipid levels, liver tests, and screening for infections.

For Children

• Use in adolescents should be limited to patients for whom abrocitinib is prescribed by a specialist; safety and effectiveness in children younger than 12 years have not been established.
• Pediatric dosing may depend on age, body weight, kidney function, liver function, infection risk, and local prescribing guidance.
• Do not use in children or adolescents without specialist medical supervision.

Side Effects

• Common effects may include nausea, headache, dizziness, acne, vomiting, abdominal discomfort, upper-respiratory symptoms, and increased risk of herpes infections.
• Laboratory changes may include reduced platelet or lymphocyte counts, changes in cholesterol levels, and elevations in liver enzymes.
• Seek urgent medical attention for fever, persistent cough, breathing difficulty, painful skin rash or blisters, severe abdominal pain, unusual bleeding or bruising, leg swelling, chest pain, sudden weakness, or symptoms of a severe allergic reaction.
• Serious risks may include severe infections, tuberculosis or shingles, blood clots, major cardiovascular events, malignancy, significant blood-count abnormalities, and liver injury.

Contraindications

• Do not use in patients with a known allergy to abrocitinib or any tablet ingredient.
• Do not start treatment during an active serious infection, including serious bacterial, fungal, viral, or tuberculosis infection, unless specifically directed by a specialist.
• Use extreme caution or avoid treatment in patients with a history of recurrent infections, blood-cell abnormalities, active hepatitis, significant liver disease, severe kidney disease, cancer, blood clots, heart attack, stroke, or major cardiovascular risk factors.
• Screening for tuberculosis, viral hepatitis, and other clinically relevant infections may be required before and during therapy.
• Avoid live vaccines during treatment unless specifically approved by the treating clinician.
• It is generally not recommended to combine abrocitinib with other JAK inhibitors, biologic immunosuppressants, or potent immunosuppressive medicines unless specifically directed by a specialist.

Precautions & Warnings

• Interactions may occur with strong or moderate CYP2C19 inhibitors or inducers and with medicines that affect abrocitinib metabolism; dose adjustment or an alternative treatment may be required.
• Tell the prescriber about antibiotics, antifungals, anticonvulsants, HIV medicines, rifampicin, fluconazole, fluoxetine, fluvoxamine, proton-pump inhibitors, and herbal products such as St. John’s wort.
• Avoid concurrent use with other JAK inhibitors, biologic immunomodulators, potent immunosuppressants, or medicines that substantially increase infection or blood-clot risk unless specifically prescribed.
• Alcohol and food are not expected to cause a specific major interaction, but alcohol may worsen liver problems or increase overall health risks in susceptible patients.

Pregnancy

• Abrocitinib should generally be avoided during pregnancy unless the expected benefit clearly outweighs potential risk and treatment is specifically recommended by a specialist.
• Women who could become pregnant should discuss reliable contraception with their healthcare professional before and during treatment.
• Tell the prescriber immediately if pregnancy occurs or is planned; pregnancy exposure may require specialist review and follow-up.
• Breastfeeding is generally not recommended during treatment because it is not known whether abrocitinib passes into human milk and could affect an infant.